Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAM | P19021 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2642731 | 1.00 | PAM (0.46) | PAMALDH1A1TBXAS1KMT2ARAB9A | |
| SCHEMBL9574442 | 0.85 | AKR1B10 (0.52) | PAMALDH1A1TBXAS1KMT2ARAB9A | |
| SCHEMBL18979186 | 0.85 | AKR1B10 (0.52) | PAMALDH1A1TBXAS1KMT2ARAB9A | |
| SCHEMBL666894 | 0.84 | PAM (0.64) | PAMALDH1A1TBXAS1MAPTHDAC3 | |
| SCHEMBL1231739 | 0.84 | PAM (0.64) | PAMALDH1A1TBXAS1MAPTHDAC3 | |
| SCHEMBL1232837 | 0.84 | PAM (0.64) | PAMALDH1A1TBXAS1MAPTHDAC3 | |
| SCHEMBL2664660 | 0.83 | PAM (0.44) | PAMALDH1A1TBXAS1KMT2ARAB9A | |
| SCHEMBL727448 | 0.83 | HSD11B1 (0.50) | PAMALDH1A1TBXAS1KMT2ARAB9A | |
| SCHEMBL727447 | 0.83 | HSD11B1 (0.50) | PAMALDH1A1TBXAS1KMT2ARAB9A | |
| SCHEMBL13870216 | 0.83 | KMT2A (0.62) | PAMALDH1A1TBXAS1KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1509509-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2005-03-02 | — | — | EP | disclosed |
| US-20040116483-A1 | Glucagon antagonists/inverse agonists | BEHRENS CARSTEN (DK) | 2004-06-17 | — | — | US | disclosed |
| WO-2003097619-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2003-11-27 | — | — | WO | disclosed |
| US-6649641-B2 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2003-11-18 | — | — | US | disclosed |
| US-20030203946-A1 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2003-10-30 | — | — | US | disclosed |
| US-20030203946-A1 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2003-10-30 | — | — | US | disclosed |
| US-20030203946-A1 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2003-10-30 | — | — | US | disclosed |
| EP-1345890-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | Novo Nordisk A/S (DK) | 2003-09-24 | — | — | EP | disclosed |
| US-20020187982-A1 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2002-12-12 | — | — | US | disclosed |
| WO-2002040445-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2002-05-23 | — | — | WO | disclosed |
| WO-2002040445-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020187982-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | PAM 748/4885ALDH1A1 3770/4885TBXAS1 777/4885 |
| US-20030203946-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | PAM 748/4885ALDH1A1 3770/4885TBXAS1 777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.